Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection

Pharmacotherapy

Volumn 27, Issue 6, 2007, Pages 793-800

  Benator, Debra A ^a,i   Weiner, Marc H ^b   Burman, William J ^c   Vernon, Andrew A ^e   Zhao, Zhen A ^e   Khan, Awal E ^e   Jones, Brenda E ^f   Sandman, Laurie ^g   Engle, Melissa ^b   Silva Trigo, Claudia ^f   Hsyu, Poe H ^h   Becker, Mark I ^h   Peloquin, Charles A ^d  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c DENVER PUBLIC HEALTH   (United States)

^d NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f LAC USC MEDICAL CENTER   (United States)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h AGOURON PHARMACEUTICALS INC   (United States)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cytochrome P450; Drug interactions; HIV; Human immunodeficiency virus; Isoniazid; Nelfinavir; Pharmacokinetics; Rifabutin; Tuberculosis

Indexed keywords

CYTOCHROME P450; DEACETYLRIFABUTIN; DRUG METABOLITE; ISONIAZID; M 8; NELFINAVIR; RIFABUTIN; UNCLASSIFIED DRUG; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; EVALUATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PROSPECTIVE STUDY; SIDE EFFECT; TUBERCULOSIS;

ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; COHORT STUDIES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; ISONIAZID; MALE; NELFINAVIR; PROSPECTIVE STUDIES; RIFABUTIN; TUBERCULOSIS;

EID: 34249828961     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.6.793     Document Type: Article

References (28)

1. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control/Infectious Disease Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167(4):603-62.
2. Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep 2000;49(9):185-9. Available from www.cdc.gov/nchstp/tb/pubs/mmwrhtml/Maj_guide/HIV_AIDS.htm.
3. Burman WJ, Gallicano K, Peloquin CA. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibiotics. Clin Pharmacokinet 2001:40:327-41.
4. Namdar R, Ebert S, Peloquin CA. Drugs for tuberculosis. In: Piscitelli SC, Rodvold KA, eds. Drug interactions in infectious diseases, 2nd ed. Totowa, NJ: Humana, 2006:191-214.
5. Kerr BM, Daniels R, Clendeninn N. Pharmacokinetic interaction of nelfinavir with half-dose rifabutin [abstract B203]. Can J Infect Dis 1999;10(suppl B):21B.
6. U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?Menultem= Guidelines&Search=Off&GuidelinelD=7&ClassID=1. Accessed May 4, 2006.
7. U.S. Department of Health and Human Services. Public Health Service task force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Supplement: safety and toxicity of individual antiretroviral agents in pregnancy. Available from www.aidsinfo.nih.gov/ Guidelines/GuidelineDetail.aspx?Menultem=Guidelines&Search= Off&GuidelineID=9&ClassID=2. Accessed November 17, 2005.
8. Peloquin C. What is the right dose of rifampin? Int J Tuberc Lung Dis 2003;7:3-5.
9. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003;47:2118-24.
10. Burman W, Benator D, Vernon A, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006;173(3):350-6.
11. Agouron Pharmaceuticals, Inc. Viracept (nelfinavir mesylate) tables and oral powder prescribing information. La Jolla, CA; 2006. Available from www.pfizer.com/pfizer/download/uspi_viracept.pdf.
12. Peloquin CA, Namdar R, Dodge AA, Nix DE. Pharmacokinetics of isoniazid under fasting-conditions, with food and with antacids. Int J Tuberc Lung Dis 1999;3:703-10.
13. Hsyu P, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001;45(12):3445-50.
14. Hsyu P, Lillibridge J, Daniels E, Kerr BM. Pharmacokinetic Interaction of nelfinavir and methadone in intravenous drug users. Biopharm Drug Dispos 2006;27(2):61-8.
15. Centers for Disease Control and Prevention. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep 2002;51(10):214-15.
16. Weiner M, Benator D, Burman W, et al, and the Tuberculosis Trials Consortium. The association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005;40(10):1481-91.
17. Li RC, Narang PK, Pogesi I, Strolin-Benedetti M. A model based assessment of redistribution dependent elimination and bioavailability of rifabutin. Biopharm Drug Dispos 1996;17: 223-36.
18. Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis 1996;22(suppl 1):S15-22.
19. Kunin CM. Antimicrobial activity of rifabutin. Clin Infect Dis 1996;22(suppl 1):S3-14.
20. Weiner MH, Benator DA, Burman WJ, Peloquin CA, Khan AE, and the Tuberculosis Trials Consortium. Efficacy of national treatment guidelines for HIV-related tuberculosis with rifabutin and antiretroviral therapy [abstract]. Proc Am Thorac Soc 2005;2:A272.
21. Saukkonen JJ, Bernardo J, Cohn D, et al. An official ATS statement: hepatotoxicity of anti-tuberculosis therapy. Am J Respir Crit Care Med 2006;174(8):935-52.
22. Ford J, Cornforth D, Hoggard P, et al. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. Antivir Ther 2004;9:77-84.
23. LaPorte CFL, Boucher C, Back DJ, et al. Optimizing TDM in HIV clinical care: updated guideline to perform therapeutic drug monitoring (TDM) for antiretroviral agents. Version 2006. Available from www.HIVpharmacology.com.
24. Burger D, Bergshoeff A, De Groot R, et al, for the PENTA 5 Study Group. Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children. J Pediatrics 2004;145:403-5.
25. van Heeswijk RP, Khaliq Y, Gallicano KD, et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther 2004;76(6):588-97.
26. de Maat MM, Huitema AD, Mulder JW, et al. Subtherapeutic antiretroviral plasma concentration in routine clinical outpatient HIV care. Ther Drug Monit 2003;25(3):367-73.
27. Zhang KE, Wu E, Patick AK, et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother 2001;45(4):1086-93.
28. Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, Koopmans PP, Burger DM, Hekster YA. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS 2001;15:993-1000.